Anal Cancer Market is Expected to Grow by 2034

• The Anal Cancer market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• The total market size for anal cancer in the US was approximately USD 7 million in 2023, and it is expected to grow by 2034 with the approval of several new therapies.
• In the EU4 and the UK, Germany had the largest market size, estimated at around USD 1 million in 2023.

DelveInsight’s “Anal Cancer Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Anal Cancer, historical and forecasted epidemiology as well as the Anal Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Anal Cancer, offering comprehensive insights into the Anal Cancer revenue trends, prevalence, and treatment landscape. The report delves into key Anal Cancer statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Anal Cancer therapies. Additionally, we cover the landscape of Anal Cancer clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Anal Cancer treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Anal Cancer space.

To Know in detail about the Anal Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Anal Cancer Market Forecast

Some of the key facts of the Anal Cancer Market Report

• In 2023, Japan held around 2% of the anal cancer market share, a figure that is expected to grow during the study period (2020–2034).
• Key Anal Cancer Companies: Incyte Corporation, BioMimetix, Inovio Pharmaceuticals, Merck Sharp & Dohme, Dustin Deming, Advaxis, Inc., Oryx GmbH & Co. KG, and others.
• Key Anal Cancer Therapies: Retifanlimab, BMX-001, VGX-3100, 9vHPV Vaccine, Pembrolizumab, cetuximab, Axalimogene filolisbac, P16_37-63, and others
• The Anal Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Anal Cancer pipeline products will significantly revolutionize the Anal Cancer market dynamics.
• The total number of incident cases of anal cancer in the 7MM was around 20,000 in 2023, and this is expected to rise by 2034, growing at a CAGR of 2.4% during the study period (2020–2034).
• The United States had the highest number of incident cases of anal cancer among the 7MM countries, and this number is expected to grow at a CAGR of 3.6% during the study period from 2020 to 2034.
• In 2023, around 82% of patients in the United States who tested positive for HPV were diagnosed with anal cancer, with HPV identified as the main contributing factor.
• In 2023, EU4 and the UK together recorded nearly 9,000 incident cases of anal cancer, a number expected to rise by 2034. Among the EU4 countries, Germany had the highest number of incident cases.
• In Feb 2025, Averto Medical announced that the FDA granted Breakthrough Device Designation for its ColoSeal™ Intraluminal Colonic Diversion (ICD) System, which aims to improve outcomes for colorectal surgery patients by eliminating the need for a temporary ostomy.
• In January 2025, the FDA approved Amgen's KRAS G12C inhibitor, Lumakras, in combination with Vectibix for treating advanced colorectal cancer.
• In December 2024, EndoQuest Robotics gained FDA IDE approval for a clinical trial to evaluate its surgical robot in colorectal lesion removal. The trial will involve 50 participants across five US sites, focusing on the safety and performance of the system in ESD procedures (NCT06133387).
• Darmstadt, June 2024 – Merck announced it had made significant progress in its cancer drug development portfolio, including the Phase II trials of tuvusertib (an ATR inhibitor) and M9466 (a PARP1 inhibitor). In addition to these, Merck has taken M9140 (anti-CEACAM5 ADC) and M3554 (novel anti-GD2 ADC) into the clinical stage. Merck’s broader oncology strategy is also using such synergistic approaches as the two focus areas include - antibody drug conjugates or ADCs; DNA damage response inhibitors or DDR inhibitors; and next-generation immunotherapy compounds.
• Indianapolis, June 2024 – Eli Lilly revealed positive findings from an early-stage trial of olomorasib, which is a second-generation KRAS G12C inhibitor with activity observed against various solid tumors involving KRAS G12C mutations, including non-small cell lung cancer. This has been combined with KEYTRUDA® (pembrolizumab), a PD-1 inhibitor manufactured by Merck, which has shown good tolerability when used together with olomorasib in another study.
• April 2024 – The FDA approved Enhertu (trastuzumab deruxtecan) as the first HER2-directed therapy indicated for use in patients with unresectable or metastatic HER2-positive solid tumors based on three phase II trials showing meaningful responses across multiple tumor types. Thus, Enhertu’s versatility may be further reinforced through expedited endorsement to serve as a therapy option for HER2 patients who have exhausted other treatments. 

Anal Cancer Overview

Anal cancer is a rare but increasing malignancy that develops in the tissues of the anus. It is primarily associated with human papillomavirus (HPV) infection, which is detected in approximately 80-90% of cases. Other risk factors include smoking, a weakened immune system (such as in HIV-positive individuals), chronic inflammation, and a history of anal warts.

The disease commonly presents with symptoms like rectal bleeding, anal pain or pressure, a palpable lump, and changes in bowel habits. Diagnosis typically involves a combination of physical examination, anoscopy, biopsy, and imaging studies such as MRI or CT scans to assess the extent of the disease.

Squamous cell carcinoma is the most prevalent histological subtype of anal cancer. Standard treatment options include chemoradiotherapy, which combines fluoropyrimidine-based chemotherapy (such as 5-FU) with radiation therapy, significantly improving survival rates. Surgery is considered for cases resistant to chemoradiotherapy or with recurrence.

The prognosis of anal cancer largely depends on the stage at diagnosis. Early-stage cases have a favorable survival rate, while advanced or metastatic cases pose greater treatment challenges. Due to the strong link with HPV, preventive strategies like HPV vaccination (Gardasil 9) play a crucial role in reducing the incidence of anal cancer.

Anal Cancer Epidemiology

The United States reported the highest number of incident anal cancer cases in the 7MM, projected to grow at a 3.6% CAGR from 2020–2034. In 2023, HPV was the primary driver, with about 82% of HPV-positive individuals diagnosed with anal cancer. The EU4 and the UK recorded nearly 9,000 new cases in 2023, with Germany having the highest incidence. In Japan, the histological pattern differs from other markets—adenocarcinoma and other types are more common than SCC, which dominates in the rest of the 6MM.

Anal Cancer Epidemiology Segmentation

The Anal Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Anal Cancer
• Prevalent Cases of Anal Cancer by severity
• Gender-specific Prevalence of Anal Cancer
• Diagnosed Cases of Episodic and Chronic Anal Cancer

Download the report to understand which factors are driving Anal Cancer epidemiology trends @ Anal Cancer Epidemiology Forecast

Anal Cancer Competitive Landscape

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Anal Cancer market or expected to get launched during the study period. The analysis covers Anal Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Anal Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Anal Cancer Therapies and Key Companies

• Retifanlimab: Incyte Corporation
• BMX-001: BioMimetix
• VGX-3100: Inovio Pharmaceuticals
• 9vHPV Vaccine: Merck Sharp & Dohme
• Pembrolizumab: Dustin Deming
• cetuximab: AIDS Malignancy Consortium
• Axalimogene filolisbac: Advaxis, Inc.
• P16_37-63: Oryx GmbH & Co. KG

Discover more about therapies set to grab major Anal Cancer market share @ Anal Cancer Treatment Landscape

Anal Cancer Market Drivers

Rising Incidence and Growing High-Risk Populations

• Increasing rates of HPV infection, especially HPV-16, significantly elevate anal cancer risk.
• Higher prevalence among immunocompromised groups, including HIV-positive individuals, boosts demand for screening and treatment.

Advancements in Diagnostics and Screening

• Improved HPV testing, anal cytology, and high-resolution anoscopy (HRA) enable earlier detection.
• Growing awareness of pre-cancerous lesions (AIN – Anal Intraepithelial Neoplasia) supports market growth.

Shifts Toward Early Intervention and Prevention

• Widespread HPV vaccination programs (e.g., Gardasil) are improving long-term prevention efforts.
• Early treatment strategies for high-grade AIN help delay or prevent anal cancer progression.

Expanding Therapeutic Landscape

• Increasing R&D in immunotherapies (e.g., PD-1 inhibitors) and targeted therapies.
• Improved chemoradiation techniques enhance survival outcomes, encouraging adoptionStrong Unmet Needs Encourage Innovation

• Limited approved therapies for advanced/metastatic anal cancer drive pharmaceutical interest.
• Demand for better tolerability and reduced toxicity fuels development of novel options.

Anal Cancer Market Barriers

Low Disease Awareness and Underdiagnosis

• Stigma, lack of awareness, and limited routine screening lead to late-stage diagnosis.
• High-risk populations often remain underserved.

Dependence on Chemoradiation with Significant Toxicity

• The standard Nigro regimen (chemoradiation) is effective but associated with severe side effects.
• Limited alternatives restrict patient and physician choice.

Small Patient Population

• As a rare cancer, anal cancer offers lower commercial returns, slowing large-scale investment.
• Fewer clinical trials and smaller sample sizes make data generation challenging.

Access and Infrastructure Limitations

• Limited availability of high-resolution diagnostic tools (e.g., HRA) in many regions.
• Unequal access to experienced oncologists and specialized centers.

High Cost of Advanced Therapies

• Novel immunotherapies may be expensive, slowing adoption in price-sensitive markets.
• Reimbursement challenges persist, especially in emerging economies.

Scope of the Anal Cancer Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Anal Cancer Companies: Incyte Corporation, BioMimetix, Inovio Pharmaceuticals, Merck Sharp & Dohme, Dustin Deming, Advaxis, Inc., Oryx GmbH & Co. KG, and others
• Key Anal Cancer Therapies: Retifanlimab, BMX-001, VGX-3100, 9vHPV Vaccine, Pembrolizumab, cetuximab, Axalimogene filolisbac, P16_37-63, and others
• Anal Cancer Therapeutic Assessment: Anal Cancer current marketed and Anal Cancer emerging therapies
• Anal Cancer Market Dynamics: Anal Cancer market drivers and Anal Cancer market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Anal Cancer Unmet Needs, KOL’s views, Analyst’s views, Anal Cancer Market Access and Reimbursement 

To know more about Anal Cancer companies working in the treatment market, visit @ Anal Cancer Clinical Trials and Therapeutic Assessment